Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A long-term follow-up study focused on speckle tracking echocardiography

European Journal of Echocardiography

Volumn 11, Issue 10, 2010, Pages 883-888

  Sommer, Anders ^a   Poulsen, Steen Hvitfeldt ^a   Mogensen, Jens ^a   Thuesen, Leif ^a   Egeblad, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alcohol ablation; Hypertrophic cardiomyopathy; Speckle tracking; Strain

Indexed keywords

ALCOHOL;

ABLATION THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; PRIORITY JOURNAL; SPECKLE TRACKING ECHOCARDIOGRAPHY; SYSTOLE; TRANSCORONARY ABLATION OF SEPTAL HYPERTROPHY;

ANALYSIS OF VARIANCE; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ECHOCARDIOGRAPHY; ETHANOL; FEMALE; FOLLOW-UP STUDIES; HEART SEPTUM; HUMANS; LONGITUDINAL STUDIES; MALE; PACEMAKER, ARTIFICIAL; STATISTICS, NONPARAMETRIC; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 78649346153     PISSN: 15252167     EISSN: 15322114     Source Type: Journal    
DOI: 10.1093/ejechocard/jeq087     Document Type: Article

References (33)

1. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008;118:131-9.
2. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardi-omyopathy. Lancet 1995;346:211-4.
3. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 1997;95:2075-81.
4. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of25 patients. Heart 2000;83:326-31.
5. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidt HK, Gleichmann U et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstruc-tive cardiomyopathy: 7 years of experience. Eur J Echocardiogr 2004;5:347-55.
6. Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts Ret al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hyper-trophic obstructive cardiomyopathy. Circulation 2001;103:1492-6.
7. van Dockum WG, Kuijer JP, Gotte MJ, ten Cate FJ, ten Berg JM, Beek AM et al. Septal ablation in hypertrophic obstructive cardiomyopathy improves systolic myocardial function in the lateral (free) wall: a follow-up study using CMR tissue tagging and 3D strain analysis. Eur Heart J 2006;27:2833-9.
8. van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Gotte MJ et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation 2005; 111:2503-8.
9. Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH III. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy\the Baylor experience (1996-2002). Clin Cardiol 2005;28: 124-30.
10. Lakkis NM, Nagueh SF, Kleiman NS, Killip D, He ZX, Verani MS et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1998;98:1750-5.
11. Mogensen J, Egeblad H, Hansen PS, Jensen HK, Thuesen L. Percutaneous trans-luminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy A newtherapeutic option. Ugeskr Laeger 2000;162:1371-5.
12. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy Clin Res Cardiol 2007;96:856-63.
13. Jassal DS, Neilan TG, Fifer MA, Palacios IF, Lowry PA, Vlahakes GJ et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J 2006;27:1805-10.
14. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quanti-tation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-83.
15. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricle by two-dimensional echo-cardiography. American society of echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989;2:358-67.
16. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echo-cardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986;57:450-8.
17. Sasson Z, Yock PG, Hatle LK, Alderman EL, Popp RL. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:752-6.
18. Leitman M, Lysyansky P, Sidenko S, Shir V, Peleg E, Binenbaum M et al. Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function. J Am Soc Echocardiogr 2004;17:1021-9.
19. Perk G, Tunick PA, Kronzon I. Non-Doppler two-dimensional strain imaging by echocardiography\from technical considerations to clinical applications. J Am Soc Echocardiogr 2007;20:234-43.
20. Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggen E et al. Noninvasive myocardial strain measurement by speckle tracking echocardiogra-phy: validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll Cardiol 2006;47:789-93.
21. Serri K, Reant P, Lafitte M, Berhouet M, Le BV, Roudaut R et al. Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;47:1175-81.
22. Dalen H, Thorstensen A, Aase SA, Ingul CB, Torp H, Vatten LJ et al. Segmental and global longitudinal strain and strain rate based on echocardiography of 1266 healthy individuals: the HUNT study in Norway. Eur J Echocardiogr 2010; 11:176-83.
23. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. J Am Med Assoc 2002;287:1308-20.
24. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College ofCardiology Foundation Task Force on Clinical Expert Con-sensus Documents and the European Society ofCardiology Committee for Prac-tice Guidelines. Eur Heart J 2003;24:1965-91.
25. Carasso S, Yang H, Woo A, Vannan MA, Jamorski M, Wigle ED et al. Systolic myo-cardial mechanics in hypertrophic cardiomyopathy: novel concepts and impli-cations for clinical status. J Am Soc Echocardiogr 2008;21:675-83.
26. Kowalski M, Herbots L, Weidemann F, Breithardt O, Strotmann J, Davidavicius G et al. One-dimensional ultrasonic strain and strain rate imaging: a new approach to the quantitation of regional myocardial function in patients with aortic stenosis. Ultrasound Med Biol 2003;29:1085-92.
27. Bauer F, Eltchaninoff H, Tron C, Lesault PF, Agatiello C, Nercolini D et al. Acute improvement in global and regional left ventricular systolic function after percu-taneous heart valve implantation in patients with symptomatic aortic stenosis. Cir-culation 2004;110:1473-6.
28. Poulsen SH, Andersen NH, Heickendorff L, Mogensen CE. Relation between plasma amino-terminal propeptide of procollagen type III and left ventricular longitudinal strain in essential hypertension. Heart 2005;91:624-9.
29. Poulsen SH, Sogaard P, Nielsen-Kudsk JE, Egeblad H. Recovery of left ventricular systolic longitudinal strain after valve replacement in aortic stenosis and relation to natriuretic peptides. J Am Soc Echocardiogr 2007;20:877-84.
30. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ven-tricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement Circulation 1989;79:744-55.
31. Rajappan K, Rimoldi OE, Camici PG, Bellenger NG, Pennell DJ, Sheridan DJ. Func-tional changes in coronary microcirculation after valve replacement in patients with aortic stenosis. Circulation 2003;107:3170-5.
32. Maron BJ, Anan TJ, Roberts WC. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy. Circulation 1981;63:882-94.
33. Karlon WJ, McCulloch AD, Covell JW, Hunter JJ, Omens JH. Regional dysfunction correlates with myofiber disarray in transgenic mice with ventricular expression of ras. Am J Physiol Heart Circ Physiol 2000;278:H898-H906.